Products for Research Use Only

TNP

CAT: 0804-HY-110079-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-110079-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TNP is a competitive, reversible inhibitor of IP6K1 and IP3K, with IC50s of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP competitively binds to the ATP binding site of IP6K, inhibits the generation of 5-IP7, and thus relieves the inhibition of 5-IP7 on the AKT signaling pathway. TNP can enhance insulin sensitivity and promote thermogenesis in adipose tissue. TNP cannot effectively pass through the blood-brain barrier and is mainly used in the study of obesity, type 2 diabetes, and metabolic syndrome. However, TNP also inhibits CYP3A4 and may need further optimization[1][2][3].
CAS Number
519178-28-0
UNSPSC
12352005
Hazard Statement
H300, H319
Target
IPK Superfamily
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/IP3K_Inhibitor.html
Purity
99.29
Solubility
DMSO : 37.5 mg/mL (ultrasonic)
Smiles
FC(C1=CC(CNC2=NC(NCC3=CC=C([N+]([O-])=O)C=C3)=C4N=CNC4=N2)=CC=C1)(F)F
Molecular Formula
C20H16F3N7O2
Molecular Weight
443.38
Precautions
H300, H319
References & Citations
[1]Chang YT, et al. Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. Chembiochem. 2002 Sep 2;3 (9) :897-901.|[2]Ghoshal S, et al. TNP [N2- (m-Trifluorobenzyl), N6- (p-nitrobenzyl) purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway. Mol Metab. 2016 Aug 21;5 (10) :903-917.|[3]Lee S, et al. TNP and its analogs: Modulation of IP6K and CYP3A4 inhibition. J Enzyme Inhib Med Chem. 2022 Dec;37 (1) :269-279.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products